Self-harmCaMaPiNCT06440031
CaMaPi for Adolescents/Young People With a History of Self-harm and Suicidal Ideation in Jos, Nigeria
A study testing CaMaPi and TAU in people with Self-harm and Suicidal Ideation, run by Nottingham Trent University.
Trial summary
Suicide and self-harm are global disease burden that contributes significantly to years of lost life and mortality. Read more about this study
- Who is it for?
- Ages 16 to 24 yearsHealthy volunteers can take part
- Conditions the study is for
- Self-harm, Suicidal Ideation
- What is being tested?
- CaMaPi and TAU
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2024to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 24 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Patients aged 16-24 years presenting to the participating services, and emergency departments or admitted after an episode of self-harm to the participating hospitals or self-referrals.
- Participants will have to be living within the catchment area of the participating practices, services and hospitals.
- Not needing inpatient psychiatric treatment.
Who cannot join
- Severe mental illness (such as Psychotic disorder).
- Conditions limiting engagement with assessment/intervention.
- Temporary resident unlikely to be available for follow up.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Culturally-adapted Manual-assisted Psychological Intervention (CaMaPi) for Adolescents/Young People With a History of Self-harm and Suicidal Ideation in Jos, Nigeria
Suicide and self-harm are global disease burden that contributes significantly to years of lost life and mortality.
Read the detailed description
Self-harm and suicidal ideation represent a significant global public health concern (Knipe et al., 2022), affecting about 14.6 million people yearly (Nichols et al., 2021). Globally, over 700 000 people die by suicide annually (World Health Organization -- WHO, 2023).
Suicide is the fourth leading cause of death among 15-29-year-olds, and 77% of global suicides occur in low- and middle-income countries, including Nigeria (WHO, 2023). The psychological impact of suicidal ideation includes continuing high tendencies of self-harm (Jidong et al., 2024).
Despite the increasing rates of suicide and self-harm in Nigeria, this topic is understudied, with no culturally appropriate or sustainable psychological interventions.
- Conditions
- Self-harm, Suicidal Ideation
- Being tested
- CaMaPi, TAU
- Medical subject headings
- Self-Injurious Behavior, Suicidal Ideation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CaMaPiBehavioural
CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
TAUOther
Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
| Study group | Role | What they receive |
|---|---|---|
| CaMaPi | Experimental | Not described Receives: Behavioral: CaMaPi |
| TAU | Active comparator | Not described Receives: Other: TAU |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in acceptance and satisfaction with the intervention
Primary outcome measure would be assessed using the Service Satisfaction Scale
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Secondary outcomes (6)
Change in suicidal ideation
Secondary outcome measure would be assessed using the Beck Scale for Suicide Ideation
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in hopelessness
Secondary outcome measure would be assessed using the Beck Hopelessness Scale
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in Health Status
Secondary outcome measure would be assessed using the EQ-5D-5L quality of health scale
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in repetition rate's of self-harm
Secondary outcome measure would be assessed using an adapted Suicide Attempt Self-Injury Interview
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in use of health services
Secondary outcome measure would be assessed using Client Service Receipt Inventory
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in psychological distress
Secondary outcome measure would be assessed using Kessler Psychological Distress Scale
Measured: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2024
- Study start1 Jul 2024 (estimated)
- Primary completion30 Jun 2025 (estimated)
- Study completion30 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Self-harmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nottingham Trent University
- Sponsor type
- University, hospital or other
- Collaborators
- University of Manchester, Jos University Teaching Hospital, Teesside University
- Responsible party
- Principal investigator, Dr Dung Jidong, PhD, Nottingham Trent University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06440031
- Sponsor's protocol ID
- 0000-0001-5034-0335f
- Acronym
- CaMaPi
- Status last verified
- May 2024
- First submitted
- 28 May 2024
- Last updated
- 3 Jun 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Jidong DE, Ike TJ, Taru MY, Pwajok JY, Nwoga CN, Jidong JE, Mwankon SB, Francis C, Husain N. Culturally Adapted Manual-Assisted Psychological Intervention (CaMaPI) for Adolescents/Young People With a History of Self-Harm and Suicidal Ideation in Nigeria: A Randomised Controlled Feasibility Trial. Clin Psychol Psychother. 2025 May-Jun;32(3):e70098. doi: 10.1002/cpp.70098.
PubMed 40497640
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Culturally-adapted Manual-assisted Psychological Intervention (CaMaPi) for Adolescents/Young People With a History of Self-harm and Suicidal Ideation in Jos, Nigeria
- ClinicalTrials.gov ID
- NCT06440031
- Acronym / sponsor ID
- CaMaPi / 0000-0001-5034-0335f
- Conditions
- Self-harm, Suicidal Ideation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- Nottingham Trent UniversityUniversity, hospital or other
- Collaborators
- University of Manchester, Jos University Teaching Hospital, Teesside University
- Study start
- 1 Jul 2024 (estimated)
- Primary completion
- 30 Jun 2025 (estimated)
- Study completion
- 30 Sep 2025 (estimated)
- First posted
- 3 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Suicide and self-harm are global disease burden that contributes significantly to years of lost life and mortality.
Detailed description
Self-harm and suicidal ideation represent a significant global public health concern (Knipe et al., 2022), affecting about 14.6 million people yearly (Nichols et al., 2021). Globally, over 700 000 people die by suicide annually (World Health Organization -- WHO, 2023).
Suicide is the fourth leading cause of death among 15-29-year-olds, and 77% of global suicides occur in low- and middle-income countries, including Nigeria (WHO, 2023). The psychological impact of suicidal ideation includes continuing high tendencies of self-harm (Jidong et al., 2024).
Despite the increasing rates of suicide and self-harm in Nigeria, this topic is understudied, with no culturally appropriate or sustainable psychological interventions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CaMaPi | Experimental | Behavioral: CaMaPi |
| TAU | Active comparator | Other: TAU |
Who may qualify
- Ages
- 16 to 24 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Patients aged 16-24 years presenting to the participating services, and emergency departments or admitted after an episode of self-harm to the participating hospitals or self-referrals.
- Participants will have to be living within the catchment area of the participating practices, services and hospitals.
- Not needing inpatient psychiatric treatment.
Key exclusion criteria (3 listed)
- Severe mental illness (such as Psychotic disorder).
- Conditions limiting engagement with assessment/intervention.
- Temporary resident unlikely to be available for follow up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CaMaPiCaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months | Behavioural | CaMaPi |
| TAUTreatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service. | Other | TAU |
Primary outcome
Change in acceptance and satisfaction with the intervention
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Primary outcome measure would be assessed using the Service Satisfaction Scale
6 secondary outcomes
Change in suicidal ideation
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in hopelessness
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in Health Status
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in repetition rate's of self-harm
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in use of health services
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Change in psychological distress
Time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2024.
- Derived from this study: PubMed 40497640Jidong DE, Ike TJ, Taru MY, Pwajok JY, Nwoga CN, Jidong JE, Mwankon SB, Francis C, Husain N. Culturally Adapted Manual-Assisted Psychological Intervention (CaMaPI) for Adolescents/Young People With a History of Self-Harm and Suicidal Ideation in Nigeria: A Randomised Controlled Feasibility Trial. Clin Psychol Psychother. 2025 May-Jun;32(3):e70098. doi: 10.1002/cpp.70098.
- Individual participant dataSharing planned: No
Related trials for Self-harm
Not yet recruiting
A Pre-post Study of a Lethal Means Safety Planning Intervention for Youth at Elevated Suicide Risk in the Emergency Department
Suicidal Ideas, Suicidal Ideation
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
SERENE Low-Intensity Focused Ultrasound for Cognitive Control
Suicidal Ideation, Cognitive Control
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Enrolling by invitation
Pilot Study of a Modified Safety Planning Intervention for Elementary School-Aged Children - Main Study
Suicidal Ideation, Suicidal Behaviors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A study testing CaMaPi and TAU in people with Self-harm and Suicidal Ideation, run by Nottingham Trent University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dung Jidong, PhD (07448930519 ext. +44, dung.jidong@mamnchester.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in acceptance and satisfaction with the intervention (time frame: Change is being assessed from baseline, end of intervention at 12 weeks, and at 12 weeks post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06440031, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2024.